Home » Stocks » Burning Rock Biotech

Burning Rock Biotech Ltd. (BNR)

Stock Price: $26.67 USD -0.32 (-1.19%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.31B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 101.78M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $26.67
Previous Close $26.99
Change ($) -0.32
Change (%) -1.19%
Day's Open 26.81
Day's Range 25.58 - 26.99
Day's Volume 282,727
52-Week Range 22.50 - 32.40

More Stats

Market Cap 2.31B
Enterprise Value 2.22B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 101.78M
Float 4.30M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 22.01
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 87.68M
Net Cash / Share 1.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$31.09*
Low
31.1
Current: 26.67
High
31.1
Target: 31.09
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Burning Rock Biotech Ltd.
Country China
Employees 753
CEO Yu Sheng Han

Stock Information

Ticker Symbol BNR
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: BNR
IPO Date June 12, 2020

Description

Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China.